AP3595A - Novel gp41 antigens - Google Patents
Novel gp41 antigensInfo
- Publication number
- AP3595A AP3595A AP2011005854A AP2011005854A AP3595A AP 3595 A AP3595 A AP 3595A AP 2011005854 A AP2011005854 A AP 2011005854A AP 2011005854 A AP2011005854 A AP 2011005854A AP 3595 A AP3595 A AP 3595A
- Authority
- AP
- ARIPO
- Prior art keywords
- antigens
- novel
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/21—Retroviridae, e.g. equine infectious anemia virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5258—Virus-like particles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
- A61K2039/541—Mucosal route
- A61K2039/543—Mucosal route intranasal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
- C12N2740/15022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
- C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
- C12N2740/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Public Health (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Communicable Diseases (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Gastroenterology & Hepatology (AREA)
- General Chemical & Material Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Hematology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- AIDS & HIV (AREA)
- Oncology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US20221509P | 2009-02-06 | 2009-02-06 | |
PCT/EP2010/051522 WO2010089400A1 (en) | 2009-02-06 | 2010-02-08 | Novel gp41 antigens |
Publications (2)
Publication Number | Publication Date |
---|---|
AP2011005854A0 AP2011005854A0 (en) | 2011-08-31 |
AP3595A true AP3595A (en) | 2016-02-17 |
Family
ID=42104745
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AP2011005854A AP3595A (en) | 2009-02-06 | 2010-02-08 | Novel gp41 antigens |
Country Status (12)
Country | Link |
---|---|
US (1) | US8765137B2 (xx) |
EP (1) | EP2393510A1 (xx) |
KR (1) | KR101756202B1 (xx) |
CN (1) | CN102307592A (xx) |
AP (1) | AP3595A (xx) |
BR (1) | BRPI1008671A2 (xx) |
CA (1) | CA2750058C (xx) |
EA (1) | EA021191B1 (xx) |
MX (1) | MX2011007703A (xx) |
UA (1) | UA108469C2 (xx) |
WO (1) | WO2010089400A1 (xx) |
ZA (1) | ZA201105396B (xx) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR102254420B1 (ko) | 2019-09-02 | 2021-05-21 | 박무순 | 약용 및 식용 천연물 복합 발효액을 유효성분으로 함유하는 항균 조성물 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005010033A1 (en) * | 2003-07-30 | 2005-02-03 | Mymetics Corporation | New soluble and stabilized trimeric form of gp41 polypeptides |
WO2006117586A1 (en) * | 2005-05-02 | 2006-11-09 | Mymetics Corporation | Antibody or a fragment thereof, having neutralizing activity against hiv but not against il2 |
WO2007099446A2 (en) * | 2006-03-03 | 2007-09-07 | Mymetics Corporation | Virosome-like vesicles comprising gp41-derived antigens |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0538437B1 (en) | 1991-05-08 | 1999-08-04 | SCHWEIZ. SERUM- & IMPFINSTITUT BERN | Immunostimulating and immunopotentiating reconstituted influenza virosomes and vaccines containing them |
FR2771011B1 (fr) | 1997-11-17 | 2000-01-28 | Hippocampe | Obtention de vaccins destines a prevenir les effets pathogenes associes a une infection retrovirale |
BR0303362A (pt) * | 2002-03-06 | 2005-07-19 | Univ Arizona State | Composição e método para melhorar uma resposta imune em um animal, método para distribuir uma proteìna de carga em uma célula de animal, célula viva geneticamente modificada, e, método para a construção de uma proteìna de fusão para melhorar a resposta imune em um animal |
EA008497B1 (ru) | 2002-11-21 | 2007-06-29 | Певион Биотех Лтд. | Высокоэффективные способные к слиянию везикулы, способ их получения и фармацевтическая композиция, их содержащая |
EP1447080A1 (en) | 2003-02-13 | 2004-08-18 | Bestewil Holding B.V. | Method for producing virosome-like particles |
US7198791B2 (en) | 2003-03-03 | 2007-04-03 | Pluschke, Gerd Et Al. | Compositions and methods for the generation of protective immune responses against malaria |
WO2005001033A2 (en) | 2003-05-22 | 2005-01-06 | The Cleveland Clinic Foundation | Tolerance induction and maintenance in hematopoietic stem cell allografts |
AR056245A1 (es) | 2003-06-19 | 2007-10-03 | Bestewil Holding Bv | Membranas virales reconstituidas funcionales que contienen un coadyuvante |
EP1805204A2 (en) | 2005-09-14 | 2007-07-11 | Novetide Ltd. | Process for production of bivalirudin |
-
2010
- 2010-02-08 EP EP10703186A patent/EP2393510A1/en not_active Ceased
- 2010-02-08 CN CN2010800070146A patent/CN102307592A/zh active Pending
- 2010-02-08 AP AP2011005854A patent/AP3595A/xx active
- 2010-02-08 KR KR1020117019770A patent/KR101756202B1/ko active IP Right Grant
- 2010-02-08 US US13/144,000 patent/US8765137B2/en active Active
- 2010-02-08 CA CA2750058A patent/CA2750058C/en active Active
- 2010-02-08 BR BRPI1008671A patent/BRPI1008671A2/pt not_active Application Discontinuation
- 2010-02-08 WO PCT/EP2010/051522 patent/WO2010089400A1/en active Application Filing
- 2010-02-08 EA EA201190096A patent/EA021191B1/ru not_active IP Right Cessation
- 2010-02-08 MX MX2011007703A patent/MX2011007703A/es active IP Right Grant
- 2010-08-02 UA UAA201109903A patent/UA108469C2/ru unknown
-
2011
- 2011-07-21 ZA ZA2011/05396A patent/ZA201105396B/en unknown
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005010033A1 (en) * | 2003-07-30 | 2005-02-03 | Mymetics Corporation | New soluble and stabilized trimeric form of gp41 polypeptides |
WO2006117586A1 (en) * | 2005-05-02 | 2006-11-09 | Mymetics Corporation | Antibody or a fragment thereof, having neutralizing activity against hiv but not against il2 |
WO2007099446A2 (en) * | 2006-03-03 | 2007-09-07 | Mymetics Corporation | Virosome-like vesicles comprising gp41-derived antigens |
WO2007099387A1 (en) * | 2006-03-03 | 2007-09-07 | Mymetics Corporation | Virosome-like vesicles comprising gp41-derived antigens |
Non-Patent Citations (2)
Title |
---|
MATOBA N. ET AL.: "Humoral immune responses by prime-boost heterologous route immunizations with CTB-MPR649-684, a mucosal subunit HIV/AIDS vaccine candidate", VACCINE, ELSEVIER LTD, GB LNKD-DOI:10.1016/J. VACCINE. 2006.03.045, vol. 24, no. 23, 5 June 2006 (2006-06-05), pages 5047-5055, XP025151330 * |
MATOBA NOBUYUKI ET AL.: "Transcytosis-blocking Abs elicited by an oligomeric immunogen based on the membrane proximal region of HIV-1 gp41 target non-neutralizing epitopes", CURRENT HIV RESEARCH, vol. 6, no. 3, May 2008 (2008-05), pages 218-229, XP009132624 * |
Also Published As
Publication number | Publication date |
---|---|
EP2393510A1 (en) | 2011-12-14 |
KR101756202B1 (ko) | 2017-07-10 |
CN102307592A (zh) | 2012-01-04 |
KR20110125224A (ko) | 2011-11-18 |
EA201190096A1 (ru) | 2013-02-28 |
CA2750058C (en) | 2017-11-28 |
AU2010210071A1 (en) | 2011-07-21 |
BRPI1008671A2 (pt) | 2016-03-08 |
CA2750058A1 (en) | 2010-08-12 |
ZA201105396B (en) | 2012-04-25 |
US8765137B2 (en) | 2014-07-01 |
UA108469C2 (xx) | 2015-05-12 |
AP2011005854A0 (en) | 2011-08-31 |
EA021191B1 (ru) | 2015-04-30 |
US20110311615A1 (en) | 2011-12-22 |
MX2011007703A (es) | 2011-09-28 |
WO2010089400A1 (en) | 2010-08-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL214996A0 (en) | Anti-bcma antibodies | |
GB0920127D0 (en) | Antibodies | |
GB0909906D0 (en) | Antibodies | |
ZA201104545B (en) | Anti-siglec-15 antibody | |
IL217008A0 (en) | Vaccine | |
EP2429585A4 (en) | VACCINE IMMUNOTHERAPY | |
EP2427496A4 (en) | ANTI-VEGF-D ANTIBODIES | |
IL225667A0 (en) | A new antigen | |
GB0905570D0 (en) | Combined vaccines | |
GB0920324D0 (en) | Antibodies | |
EP2426149A4 (en) | ANTI-CADHERIN ANTIBODY | |
HK1170745A1 (en) | Antibodies against il-17br il-17br | |
GB201006165D0 (en) | Vaccine | |
GB0907935D0 (en) | Vaccines | |
IL216102A0 (en) | Combined measles-malaria vaccine | |
GB201000522D0 (en) | Vaccine | |
GB2473934B (en) | Anti-VEEV antibody | |
EP2499256A4 (en) | ANTI-C-MPL ANTIBODIES | |
ZA201105357B (en) | Splitting gp41 | |
EP2424892A4 (en) | DC-STAMP ANTIBODY | |
IL217194A0 (en) | Vaccine | |
AP3595A (en) | Novel gp41 antigens | |
GB0908945D0 (en) | Antibodies | |
GB0908885D0 (en) | Mycobacterial antigens | |
GB0911712D0 (en) | Antibody |